We have not yet commercialized any products and we may never be able to do so. We do not know when or if we will complete Aramchol’s and any future product candidates development efforts, obtain regulatory approval for Aramchol and any future product candidates or successfully commercialize any approved products. Even if we are successful in developing products that are approved for marketing, we will not be successful unless these products gain market acceptance for appropriate indications at favorable reimbursement rates. The degree of market acceptance for these products will depend on a number of factors, including:

Because ADPR is known to activate TRPM2 in order to elicit Ca2+ release from intracellular stores15,16, we focused on studying TRPM2 to explore its possible role in perforin exocytosis. To this end, we first examined whether CD38 co-localized with TRPM2 in NK cells. CD38 and TRPM2 were dispersed at different locations in non-stimulated NK cells. However, contact with B16F10 cells changed the locations of CD38 and TRPM2, concentrating them at the immunological synapse formed between NK cells and B16F10 cells (Fig. 6a). Furthermore, CD38 and TRPM2 proteins appeared to physically interact only after NK cells were stimulated by B16F10 cells, as judged by the co-immunoprecipitation of TRPM2 with CD38 (Fig. 6b). These results suggest that the formation of ADPR by CD38 in NK cells leads to activation of TRPM2 channels, due to the proximity of TRPM2 and CD38.

Sommer, T. & Wolf, D. H. The ubiquitin-proteasome-system. Biochimica et biophysica acta. 1843, 1, (2014).

A third patent family discloses the use of FABACs in the treatment, prevention and inhibition of progression of Alzheimer’s Disease, cerebral amyloid angiopathy and other brain diseases characterized by amyloid plaque deposits. This patent family includes an issued European patent that was validated in France, Germany, Switzerland and the United Kingdom. If the appropriate maintenance, renewal, annuity or other governmental fees are paid, the non-extended term for this patent family is due to expire on February 1, 2030. 

        Our management, including our Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on management’s assessment and those criteria, management concluded that our internal control over financial reporting was effective as of December 31, 2018.

        Our success depends, and will likely continue to depend, upon our ability to hire, retain the services of our current executive officers, directors, principal consultants and others. In addition, we have established relationships with universities and research institutions which have historically provided, and continue to provide, us with access to research laboratories, clinical trials, facilities and patients. Our ability to compete in the biotechnology and pharmaceuticals industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel.

What we want is hgh to bind to its receptor, start its signaling cascade and vanish, not stay around too long and cause all kinds of havoc.

Prospective investors should be aware that this summary does not address the tax consequences to investors who are not U.S. Holders. Prospective investors should consult their own tax advisors as to the particular tax considerations applicable to them relating to the purchase, ownership and disposition of our ordinary shares, including the applicability of U.S. federal, state and local tax laws and non-U.S. tax laws.

In addition, certain provisions of the Articles may have the effect of rendering more difficult or discouraging an acquisition of the Company deemed undesirable by the Board. The classification of the Board into three classes with terms of approximately three years each, and the requirement under Companies Law to have at least two external directors, who cannot readily be removed from office, may make it more difficult for shareholders who oppose the policies of the Board to remove a majority of the then current directors from office quickly. It may also, in some circumstances, together with the other provisions of the Articles and Israeli law, deter or delay potential future merger, acquisition, tender or takeover offers, proxy contests or changes in control or management of the Company.

Yes to all, we could list so many, the work of Luther Burbank fascinates me still. And to clarify, I did not mean to point out Einstein’s humanness, as all great scientists will take a blind path at some point. I was only was using it as an example to refer back to the post about never revisiting the idea of God because there is nothing “factual”. Do we know what we think we know? It quickly become philosophical as I think Paul mentioned.

        We do not independently conduct clinical trials of any of our product candidates. We rely on third parties, such as contract research organizations, or CROs, clinical data management organizations, medical institutions and clinical investigators, to conduct these clinical trials and expect to rely on these third parties to conduct clinical trials of any other product candidate that we develop. Any of these third parties may terminate their engagements with us under certain circumstances. We may not be able to enter into alternative arrangements or do so on commercially reasonable terms. In addition, there is a natural transition period when a new contract research organization begins work. As a result, delays would likely occur, which could negatively impact our ability to meet our expected clinical development timelines and harm our business, financial condition and prospects.

        Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to the product candidate.